Reason for request
Inclusion of the list of medicines reimbursed by National Insurance and approved for use by hospitals. .
Clinical Benefit
| Substantial |
The actual benefit of these drugs is substantial. |
Clinical Added Value
| minor |
INOVELON offers a minor (level IV) improvement in actual benefit in the therapeutic management of patients aged 4 and over with Lennox-Gastaut syndrome that is resistant to first-line treatments. |
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
sU14fWMfYuMhBHMV
